老化胆固醇系统对粉样蛋白病理的选择性脆弱性,由诱导的APP过度表达揭示出来
Kan Xie1, Devon Ryan1,2, Susanne Schröder1
1Translational Biogerontology Lab, German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1/99, Bonn, 53127, Germany.
Journal of neuroinflammation
|January 6, 2026
概括
老龄化加剧了阿尔茨海默病 (AD) 对粉样β (Aβ) 毒性的敏感性,特别是影响胆固醇系统. 这项研究揭示了与年龄相关的认知和运动缺陷,独立于Aβ负担的增加.
科学领域:
- 神经科学是一个神经科学.
- 衰老研究研究 衰老研究
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,与粉样β (Aβ) 和病理有关.
- 老龄化是阿尔茨海默病的主要危险因素,但其对Aβ毒性敏感性的直接影响尚不清楚.
研究的目的:
- 调查年龄如何影响对粉样β (Aβ) 毒性的敏感性.
- 在AD的小鼠模型中探索认知功能,病理和分子途径的与年龄相关的变化.
主要方法:
- 使用了一种可以诱导四环素的小鼠模型,表达突变的人类APP (APPSweInd).
- 在中年 (6-18个月) 和老年 (12-24个月) 老鼠中启动了转基因表达.
- 一年后评估行为,Aβ病理,炎症,自和大脑基因表达.
主要成果:
- 年龄较大的表达APP的小鼠表现出认知障碍,过度活跃和运动缺陷,这些缺陷在年轻的小鼠中没有见过.
- 在不同年龄组中,APP表达,Aβ沉积,炎症和自流是相似的.
- 转录组分析显示,在老年APP诱导的小鼠中,胆能系统基因的选择性下调.
结论:
- 年龄会增加大脑对Aβ毒性的敏感性,特别是针对胆固醇系统,而不是增加Aβ负担.
- 这种诱导模型对于研究衰老和AD病理之间的相互作用是有价值的.
- 这些发现可能有助于识别导致AD进展的与年龄相关的因素.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K


